JAMA Dermatology
Peer-reviewed journalWikipedia
19
MENTIONS
12
EPISODES
10
PODCASTS
Search complete. 19 mentions across 12 episodes found for "JAMA Dermatology".
Sep 9, 2026
MichaelGUEST
Oh, it's not reducing melanoma mortality on a population level.
MichaelGUEST
There was a recent article in JAMA Dermatology.
MichaelGUEST
This is in 2026, a study done in Germany from 2009 to 2022.
MichaelGUEST
The population-based study didn't reduce melanoma mortality when they had population-level cancer screening compared to the other neighboring countries.
Ann SlessoritisHOST
We're always interested in the personal side of our guests.
Ann SlessoritisHOST
And so I want to start with, there's a recent JAMA Dermatology systematic review of prospective melanoma studies, and it found that AI performed at the level comparable to dermatologists on pulled prospective evidence overall and it did show that there was only one study that evaluated dermatologists assisted by ai so overall the pulled study was 80% sensitivity, 76% specificity, but the AI and dermatology assisted was 92% sensitive and 84% specific.
Ann SlessoritisHOST
So it was better.
Ann SlessoritisHOST
The AI assisted was better, but it was only one study of the systematic review.
Ayman GradaGUEST
Yes, I read this article and it's very interesting.
Ayman GradaGUEST
So in my opinion, for some tasks, yes, but the dermatologist level is often used too broadly.
Ayman GradaGUEST
This 2026 JAMA dermatology meta-analysis of a prospective melanoma studies that, as you said, they found fairly comparable diagnostic performance between AI and dermatologists.
Ayman GradaGUEST
But there's another 2026 study that compared more than 650 physicians with modern AI models on more complex skin cancer cases.
Alex MercerHOST
They call Lizria the first and only targeted therapy approved for dermatomyositis, and it cleared after priority review and orphan drug designation.
Alex MercerHOST
Valor ran in the New England Journal in March with skin-specific secondary endpoints in JAMA Dermatology this month.
Maya PatelHOST
Here's the line most people will skim past.
Maya PatelHOST
The indication carries no restriction on disease activity, clinical presentation, or prior treatment.
Ellie RashidHOST
I mean, I say that as someone that's not been able to build it into my routine for very many years, but, um, now, you know, there are so many YouTube videos that can just teach you how to do it, inexpensive equipment, and you can just get on with it.
Ellie RashidHOST
The other study that I find super interesting is the one that was published in, um, in JAMA Dermatology, and that was looking at women, looked at, like, over 80,000 women, and women that were physically active had less incidents of developing psoriasis.
Ellie RashidHOST
And, um, the more active they were, um, the severity of their psoriasis was also less than those that were less active.
Ellie RashidHOST
So this doesn't show cause, but I just think it's so interesting to even huge numbers, just even looking at how often they developed psoriasis.
Alex MercerHOST
They call Lysria the first and only targeted therapy approved for dermatomyositis, and it cleared after priority review and orphan drug designation.
Alex MercerHOST
Valor ran in the New England Journal in March with skin-specific secondary endpoints in JAMA Dermatology this month.
Maya PatelHOST
Here's the line most people will skim past.
Maya PatelHOST
The indication carries no restriction on disease activity, clinical presentation, or prior treatment.
Jeff StarkHOST
And hearing you talk about some of those really stringent measures, like a body surface area of zero, takes me back to Elizabeth's story when she was living with a body surface area of 10% and how different zero is from 10%.
Jeff StarkHOST
Coming back to that topic a little more, Dr. Armstrong, I know that you were involved in the research as well as the development of criteria for the on-treatment remission concept that was published last year in JAMA Dermatology.
Jeff StarkHOST
How are we officially defining on-treatment remission in psoriasis in 2026?
April ArmstrongGUEST
Yes, I gave you a very slight peek earlier.
speaker_0HOST
So to get to the bottom of this, we have pulled together a pretty heavy-hitting stack of sources for you.
speaker_0HOST
We're looking at massive clinical data from JAMA Dermatology, some really precise biomechanical studies published in plastic and reconstructive surgery, and of course, the frontline insights of global aesthetic practitioners.
speaker_1HOST
It's a great mix of data and real world application.
speaker_0HOST
It really is.
speaker_1HOST
No, it certainly doesn't.
speaker_0HOST
So how does this mechanical advantage translate when you multiply it across millions of real world scenarios?
speaker_1HOST
Well, to map that transition from the lab to the clinic, we turn to a pivotal twenty twenty-one study by Dr. Murad Alam, and that was published in JAMA Dermatology.
speaker_0HOST
Right.
speaker_0HOST
It really is.
speaker_0HOST
Plus, JAMA Dermatology studies and advanced training guides from aesthetic academies.
speaker_0HOST
So we are going to decode why understanding the microscopic layers and planes in the face is the absolute key to safety.
speaker_1GUEST
Because what happens beneath the surface during a cosmetic tweak is...
speaker_1GUEST
Good place to start.
speaker_0HOST
Because I think this perfectly illustrates the extreme danger of treating a 3D structure like a flat drawing.
speaker_0HOST
There's this study published in JAMA Dermatology by Dr. Murad Alam, and it looked at the rates of vascular occlusion.
speaker_1GUEST
Right, that nightmare blockage we just talked about.
Courtney SmithGUEST
But obviously it's not large enough robust study to really make population level, you know, conclusions on.
Courtney SmithGUEST
And so, like, kind of going off of that, there was a JAMA Dermatology paper that was published around 2020 that just focused on transmasculine individuals that were mostly adult, and they didn't stratify by age, and so that was a big issue in the data in the past that we didn't have this pediatric specific data, and so we didn't know, okay, after you start testosterone as a adolescent, how long is it before you develop acne? And that is going to inform care in the clinic because if I can give you something preventatively, give you retinoids or any other topicals before you develop that acne and also counsel you on that as an adolescent, maybe I can stop your development of scarring, other sequelae that can be very long-term.
Courtney SmithGUEST
And so there was some data out there showing that there was an increase in acne incidents overall with testosterone use, but there was no pediatric specific data that was population level.
Jen DawsonHOST
Dr.
Claudia HammondHOST
Now, we've talked before on Health Check about medical practices which have seen white skin as the default, which can mean that symptoms get missed in people with darker skin.
Claudia HammondHOST
Now, there's a new example highlighted in the journal JAMA Dermatology involving something known as post-inflammatory hyperpigmentation.
Claudia HammondHOST
That's a very long name there.
Vanessa AppiahGUEST
Mm.
2 more episodes mention JAMA Dermatology.
Create an account to see the whole feed, search across every transcript, and follow the entities you care about.